Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pharmacy Technology"
DOI: 10.1177/87551225221116010
Abstract: Objective: To review clinical data regarding the newly approved drug setmelanotide, an injectable melanocortin 4 receptor (MC4R) agonist, for chronic weight management in adults and children aged 6 years and older with monogenic obesity. Data… read more here.
Keywords: setmelanotide; obesity setmelanotide; phase; obesity ... See more keywords
Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
Sign Up to like & getrecommendations! Published in 2022 at "Life sciences"
DOI: 10.2139/ssrn.4084638
Abstract: AIMS Melanocortin 4 receptor (MC4R) has a well-established role in regulating appetite, food intake and energy homeostasis. Setmelanotide is an MC4R agonist currently approved for weight loss in obese adults and children with mutations in… read more here.
Keywords: structural analysis; receptor; setmelanotide; binding mc4r ... See more keywords
A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation
Sign Up to like & getrecommendations! Published in 2022 at "Biomolecules"
DOI: 10.3390/biom12081119
Abstract: Melanocortin 4 receptor (MC4R) is part of the leptin-melanocortin pathway and plays an essential role in mediating energy homeostasis. Mutations in the MC4R are the most frequent monogenic cause for obesity. Due to increasing numbers… read more here.
Keywords: setmelanotide like; homodimerization; mc4r; setmelanotide ... See more keywords